Screening for cerebral amyloid angiopathy based on serological biomarkers analysis using a dielectrophoretic force-driven biosensor platform
Lab on a Chip, ISSN: 1473-0189, Vol: 21, Issue: 23, Page: 4557-4565
2021
- 8Citations
- 14Captures
- 1Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations8
- Citation Indexes7
- CrossRef4
- Patent Family Citations1
- 1
- Captures14
- Readers14
- 14
- Mentions1
- News Mentions1
- 1
Most Recent News
Screening for cerebral amyloid angiopathy based on serological biomarkers analysis using a dielectrophoretic force-driven biosensor platform.
Lab Chip. 2021 Nov 1; Authors: Kim HJ, Park D, Yun G, Kim H, Kim HG, Lee KM, Hong IK, Park KC, Lee JS, Hwang KS PubMed: 34724019 Submit Comment
Article Description
We aimed to analyze plasma amyloid-β (Aβ)1-40 and Aβ1-42 using a highly sensitive dielectrophoretic-driven biosensor platform to demonstrate the possibility of precise cerebral amyloid angiopathy (CAA) diagnosis in participants classified according to Aβ-positron emission tomography (PET) positivity and the neuroimaging criteria for CAA. We prospectively recruited 25 people with non-Alzheimer's disease (non-AD) and 19 patients with Alzheimer's disease (AD), which were further classified into the CAA- and CAA+ (possible and probable CAA) groups according to the modified Boston criteria. Patients underwent plasma Aβ analysis using a highly sensitive nano-biosensor platform, Aβ-PET scanning, and detailed neuropsychological testing. As a result, the average signal levels of Aβ1-42/1-40 differed significantly between the non-AD and AD groups, and the CAA+ group exhibited significantly higher Aβ1-40 signal levels than the CAA- group in both non-AD and AD groups. The concordance between the Aβ1-40 signal level and the neuroimaging criteria for CAA was nearly perfect, with areas under the curve of 0.954 (95% confidence interval (CI) 0.856-1.000), 0.969 (0.894-1.000), 0.867 (0.648-1.000), and 1.000 (1.000-1.000) in the non-AD/CAA- vs. non-AD/possible CAA, non-AD/CAA- vs. non-AD/probable CAA, AD/CAA- vs. AD/possible CAA, and AD/CAA- vs. AD/probable CAA groups, respectively. Higher Aβ1-40 signal levels were significantly associated with the presence of CAA according to regression analyses, and the neuroimaging pattern analysis partly supported this result. Our findings suggest that measuring plasma Aβ1-40 signal levels using a highly sensitive biosensor platform could be a useful non-invasive CAA diagnostic method. This journal is
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85120374824&origin=inward; http://dx.doi.org/10.1039/d1lc00742d; http://www.ncbi.nlm.nih.gov/pubmed/34724019; https://xlink.rsc.org/?DOI=D1LC00742D; https://dx.doi.org/10.1039/d1lc00742d; https://pubs.rsc.org/en/content/articlelanding/2021/lc/d1lc00742d
Royal Society of Chemistry (RSC)
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know